Palisade Bio
Tracked across 1 events · 6 articles · First seen Sep 23, 2026 · Last active Sep 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Palisade Bio, Inc. (Nasdaq: PALI) announced that Canada — Health Canada has cleared its Clinical Trial Application (CTA) for ASCENTRA-UC, a global Phase 2 study evaluating PALI-2108 in patients with moderately to severely active ulcerative…
Impact: Palisade Bio is the central entity of this event, receiving Canada — Health Canada clearance for its ASCENTRA-UC Phase 2 trial of PALI-2108, which expands the study into Canada and supports planned enrollment. The clearance is a positive execution milestone but shares traded down 2.96% at $1.64, indicating limited near-term market impact.
Sep 23, 2026 · 6 articles
90
Canada — Health Canada cleared clinical trial application Palisade BioHealth Canada Clears...
ERGEN INTELLIGENCE
Track Palisade Bio live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard